Micronoma receives FDA breakthrough device designation for OncobiotaLUNG, a novel liquid biopsy assay for lung carcinoma detection

Micronoma

10 January 2023 - The OncobiotaLUNG assay is the first blood microbiome driven liquid biopsy with proven effectiveness, including identifying cancer in its earliest stages.

Micronoma announced today that its OncobiotaLUNG assay received the breakthrough device designation from the FDA.

Read Micronoma press release

Michael Wonder

Posted by:

Michael Wonder